George S. Zorich Named Chief Executive Officer of Agilis Biotherapeutics

George S. Zorich Named Chief Executive Officer of Agilis Biotherapeutics

<0> Agilis BiotherapeuticsGeorge S. Zorich, 301-944-2884Chief Executive Officer </0>

, a synthetic biology-based company focused on developing DNA-based therapeutics for rare genetic diseases, announced today that George S. Zorich has been named Chief Executive Officer of the company. Mr. Zorich previously served as President of General Injectables and Vaccines, Inc. (GIV), President of U.S. operations for Sabex USA, and President of North American operations for Bioniche Pharma, three enterprises that were sold to global pharmaceutical companies under Mr. Zorich’s leadership. Mr. Zorich began his career with Eli Lilly and Company and has held various executive positions across a variety of businesses, including branded products, generics, and distribution.

“Agilis is thrilled to have George join our efforts in developing new therapies for rare diseases utilizing synthetic biology approaches,” said G. Houston Hall, Managing Director of Agilis Biotherapeutics. “George is a highly accomplished leader who brings to Agilis both strategic vision and a track record of significant operating results. Agilis is well-positioned to advance our Friedreich’s ataxia program with our collaborator . I cannot imagine a better person to add to our team, and I look forward to working closely with George in the development of life changing medicines.”

“It is a very exciting time at Agilis,” said Mr. Zorich. “I’m delighted to be joining this team of highly regarded researchers and business leaders and working in collaboration with Intrexon to potentially develop novel approaches to treating rare genetic diseases with synthetic biology. I look forward to helping the team move rapidly towards key development decisions with a very exciting DNA-based therapeutic.”

Agilis Biotherapeutics, LLC, is a biotechnology company focused on designing and engineering first-in-class DNA-based therapeutics to improve and save the lives of patients affected by life-threatening or fatal rare diseases for which there are limited or no treatment options. We believe that engineered DNA-based therapeutics provide the ability to target underlying disease mechanisms with tightly-controlled multigenic modalities leading to “functional cures” for patients with these diseases.

We invite you to visit our website at .

Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release.

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Gilead names Dickinson to CFO role; MedImmune CSO Herbst nabs CSO job at Pyxis; Checkmate picks up Wooldridge for CMO.